# PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

Study · id `cardio:ct-nct03168776` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03168776](<https://clinicaltrials.gov/study/NCT03168776>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03168776

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1629 participants.

## Technical summary

Registry record NCT03168776. Randomized; single masking; primary purpose treatment. Start 2017-10-13 (actual); primary completion 2020-10-01 (actual). Results posted on 2026-01-27.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1629 participants (enrolled count; ClinicalTrials.gov record NCT03168776, source copy `cardio:ctgov-nct03168776-2026-01-27`, retrieved 2026-10-26)
- Started: 2017-10-13 (actual) (ClinicalTrials.gov record NCT03168776, source copy `cardio:ctgov-nct03168776-2026-01-27`, retrieved 2026-10-26)
- Primary completion: 2020-10-01 (actual) (ClinicalTrials.gov record NCT03168776, source copy `cardio:ctgov-nct03168776-2026-01-27`, retrieved 2026-10-26)
- Completion: 2024-10-01 (actual) (ClinicalTrials.gov record NCT03168776, source copy `cardio:ctgov-nct03168776-2026-01-27`, retrieved 2026-10-26)
- Results first posted: 2026-01-27 (ClinicalTrials.gov record NCT03168776, source copy `cardio:ctgov-nct03168776-2026-01-27`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; Japan; Netherlands; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT03168776, source copy `cardio:ctgov-nct03168776-2026-01-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03168776-2026-01-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
- Condition: Coronary Artery Disease
- Intervention (Device): BuMA Supreme DES
- Intervention (Device): Xience or Promus DES
- Lead sponsor: Sino Medical Sciences Technology Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Nova Vascular LLC
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Sino Medical Sciences Technology Inc. (`cardio:org-sino-medical-sciences-technology-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial (`cardio:pubmed-33820424`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ccd2c026f88ca5e4217781ac1ad701e274125f0e078cc7f8c8b59eaad80a1d5a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
